Overview

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Nivolumab
Temozolomide